1256937-27-5

1256937-27-5 structure

Name: Evolocumab
Chemical Name: (2S,5S,8S,11R,14R,17S,20S,23S,26S,29S)-29-Amino-6,19,22,25,28-pentahydroxy-2-(2-hydroxy-2-iminoethyl)-17,23-bis[4-({hydroxy[(2R,3R)-3-methyl-3,4-dihydro-2H-pyrrol-2-yl]methylene}amino)butyl]-20-isobutyl-26-isopropyl-5-methyl-8-[2-(methylsulfanyl)ethyl]-9,10,15,16-tetraoxo-11-(selanylmethyl)-14-(sulfanylmethyl)-3,4,7,12,13,18,21,24,27-nonaazadotriaconta-6,18,21,24,27-pentaene-1,32-dioic acid
CAS Number: 1256937-27-5
Molecular Formula: C₅₈H₉₇N₁₅O₁₆S₂Se
Molecular Weight: 1403.572
Create Date: 2018-07-18 06:09:02
Modify Date: 2024-01-06 10:58:37
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases[1].

Name	(2S,5S,8S,11R,14R,17S,20S,23S,26S,29S)-29-Amino-6,19,22,25,28-pentahydroxy-2-(2-hydroxy-2-iminoethyl)-17,23-bis[4-({hydroxy[(2R,3R)-3-methyl-3,4-dihydro-2H-pyrrol-2-yl]methylene}amino)butyl]-20-isobutyl-26-isopropyl-5-methyl-8-[2-(methylsulfanyl)ethyl]-9,10,15,16-tetraoxo-11-(selanylmethyl)-14-(sulfanylmethyl)-3,4,7,12,13,18,21,24,27-nonaazadotriaconta-6,18,21,24,27-pentaene-1,32-dioic acid
Synonyms	3,4,7,12,13,18,21,24,27-Nonaazadotriaconta-6,18,21,24,27-pentaene-1,32-dioic acid, 29-amino-17,23-bis[4-[[[(2R,3R)-3,4-dihydro-3-methyl-2H-pyrrol-2-yl]hydroxymethylene]amino]butyl]-6,19,22,25,28-pentahydroxy-2-(2-hydroxy-2-iminoethyl)-14-(mercaptomethyl)-5-methyl-26-(1-methylethyl)-20-(2-methylpropyl)-8-[2-(methylthio)ethyl]-9,10,15,16-tetraoxo-11-(selenylmethyl)-, (2S,5S,8S,11R,14R,17S,20S,23S,26S,29S)- (2S,5S,8S,11R,14R,17S,20S,23S,26S,29S)-29-Amino-6,19,22,25,28-pentahydroxy-2-(2-hydroxy-2-iminoethyl)-17,23-bis[4-({hydroxy[(2R,3R)-3-methyl-3,4-dihydro-2H-pyrrol-2-yl]methylene}amino)butyl]-20-isobutyl-26-isopropyl-5-methyl-8-[2-(methylsulfanyl)ethyl]-9,10,15,16-tetraoxo-11-(selanylmethyl)-14-(sulfanylmethyl)-3,4,7,12,13,18,21,24,27-nonaazadotriaconta-6,18,21,24,27-pentaene-1,32-dioic acid

Description	Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Ser/Thr Protease Research Areas >> Metabolic Disease
Target	PCSK9[1]
References	[1]. Fala L, et, al. Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Am Health Drug Benefits. 2016 Mar;9(Spec Feature):136-9.